Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Quantum Biopharma ( (TSE:QNTM) ) has shared an update.
On April 22, 2026, Quantum BioPharma Ltd. announced that its licensee Unbuzzd Wellness Inc., the company behind unbuzzd, has appointed capital-markets veteran Richard Buzbuzian as CEO in a move aimed at accelerating commercialization. Buzbuzian is tasked with leading a nationwide rollout of the clinically validated alcohol metabolism and hangover-relief beverage, beginning with expansion into South Florida and Texas, and driving broader market penetration in the fast-growing functional beverage segment.
Unbuzzd, backed by a peer-reviewed clinical study demonstrating efficacy in speeding alcohol metabolism and reducing hangover symptoms, is targeting health-conscious consumers through a clean-label, ready-to-mix powder format and a multi-channel distribution strategy spanning pharmacies, liquor stores, supermarkets and e-commerce. For Quantum BioPharma, which holds nearly 20% of Unbuzzd Wellness and a significant royalty interest, the ramp-up of national distribution in a functional beverage market projected to reach $198 billion in 2026 represents a potentially meaningful upside to its revenue diversification and positions the group at the intersection of biotech innovation and consumer wellness.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company building a portfolio of innovative assets and biotech solutions targeting neurodegenerative and metabolic disorders and alcohol misuse. Through its subsidiary Lucid Psycheceuticals, it is developing Lucid-MS, a patented new chemical entity that has shown preclinical potential to prevent and reverse myelin degradation in multiple sclerosis models.
The company also invented unbuzzd, an over-the-counter beverage that accelerates alcohol metabolism and reduces hangover symptoms, and spun out its OTC version to Unbuzzd Wellness Inc. Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness as of December 31, 2025, along with a royalty stream on unbuzzd sales and full rights to develop related products for pharmaceutical and medical uses.
Average Trading Volume: 15,947
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$24.48M
Learn more about QNTM stock on TipRanks’ Stock Analysis page.